Prostate cancer (PC3) | Breast cancer (MDA-MB-468) | ||||
---|---|---|---|---|---|

Type | Enzyme target | 2D | 3D | 2D | 3D |

Metabolic targets | FASN | N = 26 μmol/L | 7.2 μmol/L | N = 19 μmol/L | 17 μmol/L |

H = 84 μmol/L | H = 22 μmol/L | ||||

ACC | N = NC | 11 μmol/L | N = NC | NC | |

H = 11 μmol/L | H = 60 μmol/L | ||||

DGAT | N = NC | 46 μmol/L | N = NC | NC | |

H = NC | H = NC | ||||

PDHK | N = 54 μmol/L | NC | N = 17 μmol/L | 5.4 μmol/L | |

H = NC | H = 46 μmol/L | ||||

Kinase targets | Pan PI3K | N = 0.1 μmol/L | 0.02 μmol/L | N = 0.2 μmol/L | 0.14 μmol/L |

H = 0.2 μmol/L | H = 0.3 μmol/L | ||||

AKT | N = 20 μmol/L | 0.36 μmol/L | N = 8.3 μmol/L | 0.17 μmol/L | |

H = 29 μmol/L | H = 8.6 μmol/L | ||||

mTOR | N = 0.8 μmol/L | 0.1 μmol/L | N = 1 μmol/L | 0.12 μmol/L | |

H = 0.7 μmol/L | H = 1.4 μmol/L |

NOTE: In 2D growth, cells were incubated under normoxia (N) and hypoxia (H). Results are shown as concentration of the drug that inhibited 50% growth (growth inhibition 50%—GI

_{50}), calculated using GraphPrism nonlinear regression (curve fit).Abbreviation: NC, not calculated due to poor curve fit or no loss in cell viability with highest concentration.